{"id":320,"date":"2020-04-01T14:15:20","date_gmt":"2020-04-01T14:15:20","guid":{"rendered":"https:\/\/nupsala-learning.co.uk\/?p=320"},"modified":"2020-04-01T14:22:54","modified_gmt":"2020-04-01T14:22:54","slug":"arthramid-vet-2-5-polyacrylamide-hydrogel-formulation-mode-of-action-published-research-indications-for-use-dose-rate-post-injection-protocols","status":"publish","type":"post","link":"https:\/\/nupsala-learning.co.uk\/arthramid-vet-2-5-polyacrylamide-hydrogel-formulation-mode-of-action-published-research-indications-for-use-dose-rate-post-injection-protocols\/","title":{"rendered":"Arthramid Vet (2.5% polyacrylamide hydrogel) – formulation, mode of action, published research, indications for use, dose rate, post-injection protocols"},"content":{"rendered":"\n
They outline the formulation of the product and give extensive details on its mode of action. The webinar also covers various published research papers over a number of years. Indications for use for Arthramid Vet are explored as well as dose rates and post injection protocols.
Arthramid Vet is registered in New Zealand to: Innovative Medical Solutions Limited NZBN: 9429041325544, 32 Hill Road, Cambridge 3494, New Zealand. Registered pursuant to the ACVM Act 1997 Number A11596.<\/p>\n","protected":false},"excerpt":{"rendered":"
Equine vets Dr Leigh de Clifford and Dr Jason Lowe present this webinar on Arthramid Vet, a 2.5% polyacrylamide hydrogel that is registered in New Zealand for treatment of osteoarthritis in horses. <\/p>\n","protected":false},"author":4,"featured_media":322,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[65,102,72,75,27],"tags":[59],"yoast_head":"\n